|
Thursday, May 26, 2005
Targeted Molecules Acquired by Chromos
San Diego-based biopharmaceuticals firm Targeted Molecules has been acquired by Chromos, a Canadian biotceh firm. Targeted Molecules is developing two antibody products for the treatment of multiple sclerosis and acute thrombosis. Targeted Molecules is backed by GeneChem, FAT Capital, GC&H Investments, Inglewood Ventures, Linkagene, Neuro Discovery, and Trian Equities and most recently received a round of funding in 2003.
posted on Thursday, May 26, 2005
|
 RSS
 Email
Twitter
Previous news:
Friday, November 21, 2008
Thursday, November 20, 2008
Wednesday, November 19, 2008
Tuesday, November 18, 2008
Monday, November 17, 2008
|
